- Home
- KIO vs EDIT Comparison
KIO vs EDIT Comparison
Compare KIO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- EDIT
- Stock Information
- Founded
- KIO 2011
- EDIT 2013
- Country
- KIO United States
- EDIT United States
- Employees
- KIO 2400
- EDIT N/A
- Industry
- KIO Investment Managers
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIO Finance
- EDIT Health Care
- Exchange
- KIO Nasdaq
- EDIT Nasdaq
- Market Cap
- KIO 404.1M
- EDIT 327.0M
- IPO Year
- KIO N/A
- EDIT 2016
- Fundamental
- Price
- KIO $13.73
- EDIT $3.14
- Analyst Decision
- KIO
- EDIT Buy
- Analyst Count
- KIO 0
- EDIT 13
- Target Price
- KIO N/A
- EDIT $9.38
- AVG Volume (30 Days)
- KIO 136.5K
- EDIT 2.1M
- Earning Date
- KIO 01-01-0001
- EDIT 11-04-2024
- Dividend Yield
- KIO 10.82%
- EDIT N/A
- EPS Growth
- KIO N/A
- EDIT N/A
- EPS
- KIO N/A
- EDIT N/A
- Revenue
- KIO N/A
- EDIT $61,759,000.00
- Revenue This Year
- KIO N/A
- EDIT N/A
- Revenue Next Year
- KIO N/A
- EDIT N/A
- P/E Ratio
- KIO N/A
- EDIT N/A
- Revenue Growth
- KIO N/A
- EDIT 150.95
- 52 Week Low
- KIO $10.52
- EDIT $2.70
- 52 Week High
- KIO $13.59
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- KIO 31.49
- EDIT 49.77
- Support Level
- KIO $13.63
- EDIT $2.70
- Resistance Level
- KIO $14.06
- EDIT $3.40
- Average True Range (ATR)
- KIO 0.15
- EDIT 0.25
- MACD
- KIO -0.03
- EDIT 0.02
- Stochastic Oscillator
- KIO 23.48
- EDIT 49.09
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.